Transcat/$TRNS
1D1W1MYTD1Y5YMAX
Capital at risk
About Transcat
Transcat Inc is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. The Company is focused on providing services and products to high regulated industries, particularly the life sciences industry, which includes pharmaceutical, biotechnology, medical devices, and other FDA-regulated businesses, as well as aerospace and defense, and energy and utilities. It conducts business through two operating segments: Services and Distribution.
- Ticker
- $TRNS
- Sector
- Industrials
- Primary listing
- NASDAQ
- Employees
- 1,413
- Headquarters
- Rochester, United States
- Website
- www.transcat.com
Transcat Metrics
BasicAdvanced
$758M
224.85
$0.36
0.67
-
Price and volume
Market cap
$758M
Beta
0.67
52-week high
$100.00
52-week low
$50.23
Average daily volume
121K
Financial strength
Current ratio
2.492
Quick ratio
1.931
Long term debt to equity
0.458
Total debt to equity
0.458
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
42.956
Gross margin (TTM)
32.50%
Net profit margin (TTM)
0.99%
Operating margin (TTM)
4.43%
Effective tax rate (TTM)
38.56%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
2.18%
Return on equity (TTM)
1.16%
Valuation
Price to earnings (TTM)
224.847
Price to revenue (TTM)
2.172
Price to book
2.5
Price to tangible book (TTM)
-360.49
Price to free cash flow (TTM)
29.839
Free cash flow yield (TTM)
3.35%
Free cash flow per share (TTM)
2.715
Growth
Revenue change (TTM)
20.91%
Earnings per share change (TTM)
-74.99%
3-year revenue growth (CAGR)
13.78%
10-year revenue growth (CAGR)
10.74%
3-year earnings per share growth (CAGR)
-36.10%
10-year earnings per share growth (CAGR)
-5.44%
What the Analysts think about Transcat
Analyst ratings (Buy, Hold, Sell) for Transcat stock.
Analyst projections of the future price of Transcat stock.
Bulls say / Bears say
Service revenue in Q1 FY 2027 jumped 27% to $62.6 million, with service organic revenue growing double-digits and service gross margin expanding 90 bps to 33.9%, demonstrating strong operational leverage and demand in regulated end markets. (SEC)
The $13 million acquisition of SCM Metrology and Laboratories S.A. in April 2026 establishes Transcat’s first Latin American presence, broadening its service footprint for multinational customers and supporting future organic growth. (Nasdaq)
Management guides to high single-digit service organic revenue growth and further service gross margin expansion for full-year FY 2027, reflecting confidence in continued demand and strategic execution. (SEC)
Full-year fiscal 2026 net income fell 63% to $5.4 million from $14.5 million in FY 2025, driven by a 32.8% rise in operating expenses from acquisitions, highlighting pressure on profitability and integration costs. (SEC)
Transcat’s total long-term debt rose to $110.4 million at June 27, 2026 from $99.9 million at March 28, 2026, increasing leverage and interest expense risk on its balance sheet. (SEC)
Distribution gross margin in Q1 FY 2027 contracted by 380 bps year-over-year to 31.4% due to revenue mix, underlining margin compression in its lower-margin distribution segment. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 7 Sept 2026.
Transcat Financial Performance
Revenues and expenses
Transcat Earnings Performance
Company profitability
Upcoming events
No upcoming events
Transcat News
AllArticlesVideos
Transcat Expands its Biomedical Calibration Channel with the Acquisition of Southeastern Biomedical
Business Wire2 weeks ago
Transcat to Participate in Jefferies, Lake Street and D.A. Davidson Investor Conferences in September
Business Wire3 weeks ago
Transcat Q1 Earnings Call Highlights
MarketBeat1 month ago
Funds containing Transcat
AllEURUSDGBP
Fund name | Fund size | $TRNS weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
iShares MSCI World Small Cap€IUSN | €7.8B | 0.01% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.